patient_id	feature_display	tested_subfeature	therapy_name	n_mut	n_wt	n_mut_tested	n_wt_tested	mut_ic50_median	mut_ic50_mean	mut_ic50_std	wt_ic50_median	wt_ic50_mean	wt_ic50_std	pvalue_mww	statistic
KIRP-5P-A9K6	MET Amplification	MET	Crizotinib	199	1624	106	631	24.738	58.372	90.106	25.537	55.528	104.041	0.878	33754.0
KIRP-5P-A9K6	MET Amplification	MET Copy Number	Crizotinib	117	1706	60	677	24.822	57.83	90.407	25.427	55.769	103.133	0.928	20454.0
KIRP-5P-A9K6	MET Amplification	MET Copy Number Amplification	Crizotinib	82	1741	42	695	18.828	59.826	100.235	25.554	55.702	102.28	0.59	15317.0
KIRP-5P-A9K6	MAPK1 p.R148C (Missense)	MAPK1	Erlotinib	111	1712	57	695	13.186	28.021	45.954	13.427	24.126	33.722	0.926	19661.0
KIRP-5P-A9K6	MAPK1 p.R148C (Missense)	MAPK1 Somatic Variant	Erlotinib	13	1810	6	746	11.445	10.538	6.119	13.41	24.533	34.89	0.346	2738.0
KIRP-5P-A9K6	MAPK1 p.R148C (Missense)	MAPK1 Somatic Variant Missense	Erlotinib	12	1811	6	746	11.445	10.538	6.119	13.41	24.533	34.89	0.346	2738.0
KIRP-5P-A9K6	MAPK1 p.R148C (Missense)	MAPK1 Somatic Variant Missense p.R148C	Erlotinib	0	1823	0	752				13.41	24.421	34.777	nan	
